[Reduction in the need for glucocorticoids on the background of therapy with biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis: evidence from real clinical practice].
A S PotapovaA E KarateevE Y PolishchukE S FilatovaV N AmirdzhanovaAlexander M LilaPublished in: Terapevticheskii arkhiv (2024)
Against the background of intensive RA therapy, including combination of DMARDs with bDMARDs or iJAK, complete withdrawal or reduction of GC dose was achieved in less than half (45.6%) of patients after 6 months.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- clinical practice
- rheumatoid arthritis patients
- chronic kidney disease
- newly diagnosed
- ejection fraction
- ankylosing spondylitis
- interstitial lung disease
- prognostic factors
- stem cells
- bone marrow
- mesenchymal stem cells
- systemic sclerosis
- high resolution
- drug induced
- liquid chromatography